An interventional study of Standard Roux-en-Y gastric bypass and Long alimentary limb Roux-en-Y gastric bypass in Diabetes Mellitus Type 2 in Obese, sponsored by University Hospital, Lille. Recruiting at 4 sites in France. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Obesity by University Hospital, Lille — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University Hospital, Lille.
Among the 23 studies in Obesity by University Hospital, Lille, this one is one of 2 that started in 2019, is one of 7 with no phase, and was the 16th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →5 of the 23 studies in Obesity by University Hospital, Lille are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Lille · Sites in France
Ages 18+ · Women only
University Hospital, Lille · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18–65
University Hospital, Lille · Sites in France
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2019.
This study's planned enrollment of 396 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 95 across the 8 interventional studies, 134 across the 15 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
3 of the studies in Obesity by University Hospital, Lille that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04844684University Hospital, LilleEvaluation of Cortisol and Bile Acids Metabolism in Obese Patients | 2026-12-30 |
| NCT05121090University Hospital, LilleLille Study for Childhood Health Promotion | 2027-04 |
| NCT01129297University Hospital, LilleA Biological Atlas of Severe Obesity (Biological Tissue Collection) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Obesity by University Hospital, Lille, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In patients with type 2 diabetes, Roux-en-Y gastric bypass (RYGB), which excludes a portion of the stomach and the proximal intestine from the alimentary circuit, improves glucose metabolism more rapidly and more extensively than is expected from weight loss. The mechanisms of this unique effect of gastrointestinal exclusion appear to be complex and have not yet been clarified. A recent study unveil that intestinal uptake of ingested glucose is diminished by RYGB and restricted to the common limb, where food meets bile and other digestive fluids, resulting in an overall decrease of post prandial blood glucose excursion. the hypothesize that reducing the length of the common limb, which is rarely measured and highly variable in clinical practice, may significantly affect the metabolic outcome of gastrointestinal surgical procedures. The aim of the present study is to compare the impact of two variants of Roux-en-Y gastric bypass with a short common limb, the long alimentary limb or the long biliary limb Roux-en-Y gastric bypass, on type 2 diabetes remission in severely obese patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Standard Roux-en-Y gastric bypass
Procedure: Long alimentary limb Roux-en-Y gastric bypass
Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).
Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
Rate of type 2 diabetes remission
HbA1c \< 6.5% AND fasting blood glucose \< 7.0 mmol/L in absence of antidiabetic drug
Time frame: at 12 months after surgery
Absolute weight loss (aWL in kg)
Time frame: at 1, 3, 6 and 12 months after surgery
Excess Weight Loss percentage (EWL%)
Time frame: at 1, 3, 6 and 12 months after surgery
Excess BMI Loss percentage (EBL%)
Time frame: at 1, 3, 6 and 12 months after surgery
Medical and surgical complication rates
Medical and surgical complication rates (anastomotic leaks, biliary reflux, bowel obstruction, anastomotic ulcers, anastomotic stenosis, internal hernia, chronic gastritis, esophagitis, iron deficiency anemia)
Time frame: During the month following surgery (for early complications) and from one month to 12 months postoperatively (for late complications)]
Type and severity of early and late complications for each procedure
Type and severity of early and late complications for each procedure, according to the Dindo-Clavien classification
Time frame: During the month following surgery (for early complications) and from one month to 12 months postoperatively (for late complications)]
Patient's quality of life score according to the Impact of Weight on Quality of Life (IWQOL) questionnaire
The IWQOL questionnaire to be specifically assess the effects of obesity on health-related quality of life. The five identified scales are Physical Function, Self-Esteem, Sexual Life, Public Distress, and Work. The final 20-item IWQOL includes two primary domains: Physical (7 items) and Psychosocial (13 items)
Time frame: Before surgery and at 12 after surgery
Patient's quality of life score according to the Gastrointestinal Quality of Life Index (GIQLI) questionnaire adapted to bariatric surgery.
GIQLI (gastrointestinal quality of life index) questionnaire. 36 questions, each containing 4 answers equating to a score ranging from 0 (least desirable answer) to 4 (most desirable answer). Total score range 0-144.
Time frame: Before surgery and at 12 after surgery
Change in glucose homeostasis
glucose (mg/dl)
Time frame: Before surgery and at 3, 6 and 12 months after surgery
Change in HbA1c
Changes in HbA1c(%) were assessed before and after surgery
Time frame: Before surgery and at 3, 6 and 12 months after surgery
Change in fasting glycemia
Changes in fasting blood glucose levels (mmol/L)
Time frame: Before surgery and at 3, 6 and 12 months after surgery
changes in fasting insulinemia
Changes in fasting insulinemia in microunits/mL
Time frame: Before surgery and at 3, 6 and 12 months after surgery
change in fasting c-peptide
Changes in C-peptide(ng/ml) were assessed before and after the intervention.
Time frame: Before surgery and at 3, 6 and 12 months after surgery
Number of antidiabetic treatments
Metabolic profile of glucose homeostasis assessment according to antidiabetic treatments, HbA1c level, fasting glycemia, fasting insulinemia fasting c-peptide
Time frame: Before surgery and at 3, 6 and 12 months after surgery
Changes in blood lipids profile
Changes in blood lipids profile (LDL, HDL and triglyceride concentrations) according to anitilipidemic treatments
Time frame: Before surgery and at 1, 3, 6 and 12 months after surgery
change in vitamins status assessment
vitamines profil (vitamin B1, B9, B12, and D concentration) before and 12 and 24 months after surgery
Time frame: Before surgery and at 1, 3, 6 and 12 months after surgery
change in prealbumin levels
Lower levels of prealbumin are associated with malnutrition.
Time frame: Before surgery and at 1, 3, 6 and 12 months after surgery
Started Jun 2019 (actual). Primary completion is estimated for Jun 2026, 84 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 84 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.